192939-46-1
Chemical Structure
Ximelagatran
Synonym(s): H 376/95
- CAS No.: 192939-46-1
- Formula:C24H35N5O5
- Molecular Weight:473.57
IUPAC Name: ethyl ((R)-1-cyclohexyl-2-((S)-2-((4-((Z)-N'-hydroxycarbamimidoyl)benzyl)carbamoyl)azetidin-1-yl)-2-oxoethyl)glycinate
InChIKey: ZXIBCJHYVWYIKI-PZJWPPBQSA-N
SMILES: O=C([C@@H]1CCN1C([C@@H](C2CCCCC2)NCC(OCC)=O)=O)NCC3=CC=C(C=C3)/C(N)=N/O
Biological Activity: Ximelagatran (H 376/95) is an orally active thrombin inhibitor that selectively and competitively inhibits both free and clot-bound thrombin. Ximelagatran is an anticoagulant agent with a rapid onset of anticoagulant effect, predictable, dose-dependent pharmcokinetics and pharmacodynamics[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Ximelagatran | 98.43% | Ximelagatran (H 376/95) is an orally active thrombin inhibitor that selectively and competitively inhibits both free and clot-bound thrombin. Ximelagatran is an anticoagulant agent with a rapid onset of anticoagulant effect, predictable, dose-dependent pharmcokinetics and pharmacodynamics. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Ximelagatran (Standard) | ≥98% | Ximelagatran (Standard) is the analytical standard of Ximelagatran (HY-10787). This product is intended for research and analytical applications. Ximelagatran (H 376/95) is an orally active thrombin inhibitor that selectively and competitively inhibits both free and clot-bound thrombin. Ximelagatran is an anticoagulant agent with a rapid onset of anticoagulant effect, predictable, dose-dependent pharmcoKinetics and pharmacodynamics. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Colwell CW Jr, et al. Comparison of ximelagatran, an oral direct thrombin inhibitor, with enoxaparin for the prevention of venous thromboembolism following total hip replacement. A randomized, double-blind study. J Thromb Haemost. 2003 Oct;1(10):2119-30. [Content Brief]
- [2]. Gao JH, et al. Effects of different anticoagulant drugs on the prevention of complications in patients after arthroplasty: A network meta-analysis. Medicine (Baltimore). 2017 Oct;96(40):e8059. [Content Brief]
